187 related articles for article (PubMed ID: 29448961)
1. Nuclear receptor agonist-driven modification of inflammation and amyloid pathology enhances and sustains cognitive improvements in a mouse model of Alzheimer's disease.
Casali BT; Reed-Geaghan EG; Landreth GE
J Neuroinflammation; 2018 Feb; 15(1):43. PubMed ID: 29448961
[TBL] [Abstract][Full Text] [Related]
2. Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer's Disease.
Casali BT; Corona AW; Mariani MM; Karlo JC; Ghosal K; Landreth GE
J Neurosci; 2015 Jun; 35(24):9173-81. PubMed ID: 26085639
[TBL] [Abstract][Full Text] [Related]
3. Neuronally-directed effects of RXR activation in a mouse model of Alzheimer's disease.
Mariani MM; Malm T; Lamb R; Jay TR; Neilson L; Casali B; Medarametla L; Landreth GE
Sci Rep; 2017 Feb; 7():42270. PubMed ID: 28205585
[TBL] [Abstract][Full Text] [Related]
4. ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice.
Corona AW; Kodoma N; Casali BT; Landreth GE
J Neuroimmune Pharmacol; 2016 Mar; 11(1):61-72. PubMed ID: 26175148
[TBL] [Abstract][Full Text] [Related]
5. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.
Cramer PE; Cirrito JR; Wesson DW; Lee CY; Karlo JC; Zinn AE; Casali BT; Restivo JL; Goebel WD; James MJ; Brunden KR; Wilson DA; Landreth GE
Science; 2012 Mar; 335(6075):1503-6. PubMed ID: 22323736
[TBL] [Abstract][Full Text] [Related]
6. Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.
Tai LM; Koster KP; Luo J; Lee SH; Wang YT; Collins NC; Ben Aissa M; Thatcher GRJ; LaDu MJ
J Biol Chem; 2014 Oct; 289(44):30538-30555. PubMed ID: 25217640
[TBL] [Abstract][Full Text] [Related]
7. Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice.
LaClair KD; Manaye KF; Lee DL; Allard JS; Savonenko AV; Troncoso JC; Wong PC
Mol Neurodegener; 2013 Jun; 8():18. PubMed ID: 23764200
[TBL] [Abstract][Full Text] [Related]
8. Treatment with D3 removes amyloid deposits, reduces inflammation, and improves cognition in aged AβPP/PS1 double transgenic mice.
van Groen T; Kadish I; Funke SA; Bartnik D; Willbold D
J Alzheimers Dis; 2013; 34(3):609-20. PubMed ID: 23271316
[TBL] [Abstract][Full Text] [Related]
9. Bexarotene Modulates Retinoid-X-Receptor Expression and Is Protective Against Neurotoxic Endoplasmic Reticulum Stress Response and Apoptotic Pathway Activation.
Dheer Y; Chitranshi N; Gupta V; Abbasi M; Mirzaei M; You Y; Chung R; Graham SL; Gupta V
Mol Neurobiol; 2018 Dec; 55(12):9043-9056. PubMed ID: 29637440
[TBL] [Abstract][Full Text] [Related]
10. Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer's disease.
Sakakibara Y; Sekiya M; Saito T; Saido TC; Iijima KM
BMC Neurosci; 2019 Mar; 20(1):13. PubMed ID: 30894120
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology.
Holubová M; Hrubá L; Popelová A; Bencze M; Pražienková V; Gengler S; Kratochvílová H; Haluzík M; Železná B; Kuneš J; Hölscher C; Maletínská L
Neuropharmacology; 2019 Jan; 144():377-387. PubMed ID: 30428311
[TBL] [Abstract][Full Text] [Related]
12. Astaxanthin exerts protective effects similar to bexarotene in Alzheimer's disease by modulating amyloid-beta and cholesterol homeostasis in blood-brain barrier endothelial cells.
Fanaee-Danesh E; Gali CC; Tadic J; Zandl-Lang M; Carmen Kober A; Agujetas VR; de Dios C; Tam-Amersdorfer C; Stracke A; Albrecher NM; Manavalan APC; Reiter M; Sun Y; Colell A; Madeo F; Malle E; Panzenboeck U
Biochim Biophys Acta Mol Basis Dis; 2019 Sep; 1865(9):2224-2245. PubMed ID: 31055081
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
[TBL] [Abstract][Full Text] [Related]
14. Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease.
Savage JC; Jay T; Goduni E; Quigley C; Mariani MM; Malm T; Ransohoff RM; Lamb BT; Landreth GE
J Neurosci; 2015 Apr; 35(16):6532-43. PubMed ID: 25904803
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice.
Sanchez-Ramos J; Song S; Sava V; Catlow B; Lin X; Mori T; Cao C; Arendash GW
Neuroscience; 2009 Sep; 163(1):55-72. PubMed ID: 19500657
[TBL] [Abstract][Full Text] [Related]
16. OAB-14, a bexarotene derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice.
Yuan C; Guo X; Zhou Q; Du F; Jiang W; Zhou X; Liu P; Chi T; Ji X; Gao J; Chen C; Lang H; Xu J; Liu D; Yang Y; Qiu S; Tang X; Chen G; Zou L
Biochim Biophys Acta Mol Basis Dis; 2019 Jan; 1865(1):161-180. PubMed ID: 30389579
[TBL] [Abstract][Full Text] [Related]
17. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse.
Chung E; Ji Y; Sun Y; Kascsak RJ; Kascsak RB; Mehta PD; Strittmatter SM; Wisniewski T
BMC Neurosci; 2010 Oct; 11():130. PubMed ID: 20946660
[TBL] [Abstract][Full Text] [Related]
18. Xestospongin C, a Reversible IP3 Receptor Antagonist, Alleviates the Cognitive and Pathological Impairments in APP/PS1 Mice of Alzheimer's Disease.
Wang ZJ; Zhao F; Wang CF; Zhang XM; Xiao Y; Zhou F; Wu MN; Zhang J; Qi JS; Yang W
J Alzheimers Dis; 2019; 72(4):1217-1231. PubMed ID: 31683484
[TBL] [Abstract][Full Text] [Related]
19. Retinoid X receptor activation promotes re-myelination in a very old triple transgenic mouse model of Alzheimer's disease.
Santos-Gil DF; Arboleda G; Sandoval-Hernández AG
Neurosci Lett; 2021 Apr; 750():135764. PubMed ID: 33621639
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
McClean PL; Hölscher C
Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
